Cormedix Stock Performance
| CRMD Stock | USD 10.29 0.19 1.88% |
On a scale of 0 to 100, CorMedix holds a performance score of 2. The firm shows a Beta (market volatility) of 0.65, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CorMedix's returns are expected to increase less than the market. However, during the bear market, the loss of holding CorMedix is expected to be smaller as well. Please check CorMedix's semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether CorMedix's price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in CorMedix are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain primary indicators, CorMedix exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.88 | Five Day Return (5.34) | Year To Date Return 25.18 | Ten Year Return (60.42) | All Time Return (31.40) |
Last Split Factor 1:5 | Dividend Date 2019-03-26 | Last Split Date 2019-03-26 |
1 | CorMedixs SWOT analysis defencath launch boosts stock outlook | 12/12/2024 |
2 | Is CorMedix Inc. Among Billionaire Paul Singers Top Long-Term Stock Picks | 12/19/2024 |
3 | Disposition of 11844 shares by Zelnick Kaufman Beth of CorMedix at 8.22 subject to Rule 16b-3 | 01/02/2025 |
4 | Acquisition by Erin Mistry of 62500 shares of CorMedix subject to Rule 16b-3 | 01/06/2025 |
5 | CorMedix soars on Q4 preliminary resyults, business updates | 01/07/2025 |
6 | CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates | 01/08/2025 |
7 | Disposition of 5790 shares by Hurlburt Elizabeth of CorMedix at 11.19 subject to Rule 16b-3 | 01/10/2025 |
8 | Acquisition by Duncan Gregory Scott of 25000 shares of CorMedix subject to Rule 16b-3 | 01/17/2025 |
9 | Acquisition by Stewart Robert A of 25000 shares of CorMedix subject to Rule 16b-3 | 01/22/2025 |
10 | BlackRock, Inc. Increases Stake in Cormedix Inc. | 02/05/2025 |
11 | Disposition of tradable shares by Stewart Robert A of CorMedix subject to Rule 16b-3 | 02/14/2025 |
12 | Disposition of 6044 shares by Zelnick Kaufman Beth of CorMedix at 8.77 subject to Rule 16b-3 | 02/21/2025 |
| Begin Period Cash Flow | 43.4 M |
CorMedix |
CorMedix Relative Risk vs. Return Landscape
If you would invest 986.00 in CorMedix on November 28, 2024 and sell it today you would earn a total of 43.00 from holding CorMedix or generate 4.36% return on investment over 90 days. CorMedix is currently generating 0.2005% in daily expected returns and assumes 5.3238% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than CorMedix, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CorMedix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CorMedix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CorMedix, and traders can use it to determine the average amount a CorMedix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0377
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CRMD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.32 actual daily | 47 53% of assets are more volatile |
Expected Return
| 0.2 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average CorMedix is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CorMedix by adding it to a well-diversified portfolio.
CorMedix Fundamentals Growth
CorMedix Stock prices reflect investors' perceptions of the future prospects and financial health of CorMedix, and CorMedix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CorMedix Stock performance.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 567.37 M | ||||
| Shares Outstanding | 60.68 M | ||||
| Price To Earning | (0.88) X | ||||
| Price To Book | 10.44 X | ||||
| Price To Sales | 50.92 X | ||||
| Gross Profit | 10.25 M | ||||
| EBITDA | (48.89 M) | ||||
| Net Income | (46.34 M) | ||||
| Cash And Equivalents | 64.62 M | ||||
| Cash Per Share | 1.57 X | ||||
| Total Debt | 667.63 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.40 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (38.41 M) | ||||
| Earnings Per Share | (0.80) X | ||||
| Market Capitalization | 624.37 M | ||||
| Total Asset | 82.06 M | ||||
| Retained Earnings | (321.7 M) | ||||
| Working Capital | 68.05 M | ||||
| Current Asset | 37.06 M | ||||
| Current Liabilities | 3.06 M | ||||
About CorMedix Performance
By analyzing CorMedix's fundamental ratios, stakeholders can gain valuable insights into CorMedix's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CorMedix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CorMedix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 3.4 K | 3.5 K | |
| Return On Tangible Assets | (0.51) | (0.53) | |
| Return On Capital Employed | (0.80) | (0.84) | |
| Return On Assets | (0.51) | (0.53) | |
| Return On Equity | (0.76) | (0.72) |
Things to note about CorMedix performance evaluation
Checking the ongoing alerts about CorMedix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CorMedix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CorMedix had very high historical volatility over the last 90 days | |
| Net Loss for the year was (46.34 M) with profit before overhead, payroll, taxes, and interest of 10.25 M. | |
| CorMedix currently holds about 64.62 M in cash with (38.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57. | |
| CorMedix has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: BlackRock, Inc. Increases Stake in Cormedix Inc. |
- Analyzing CorMedix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CorMedix's stock is overvalued or undervalued compared to its peers.
- Examining CorMedix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CorMedix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CorMedix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CorMedix's stock. These opinions can provide insight into CorMedix's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CorMedix Stock analysis
When running CorMedix's price analysis, check to measure CorMedix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CorMedix is operating at the current time. Most of CorMedix's value examination focuses on studying past and present price action to predict the probability of CorMedix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CorMedix's price. Additionally, you may evaluate how the addition of CorMedix to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stocks Directory Find actively traded stocks across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |